Translate
Arabic
Chinese (Simplified)
Dutch
English
French
German
Italian
Portuguese
Russian
SpanishBiocon
Fast Facts
Location: Cranbury
Industry: Life Sciences
Country of origin: India
Type of facility: Manufacturing plant
Biocon Limited, a global biopharmaceutical company headquartered in Bengaluru, India, has marked a significant milestone by inaugurating its first U.S. manufacturing facility in Cranbury. The plant, operated by its wholly-owned subsidiary Biocon Generics Inc. (BGI), opened in September 2025 and was formally launched with the attendance of New Jersey Governor Phil Murphy as the guest of honor.
The facility was originally acquired in 2023 when Biocon bought the former oral solid dosage (OSD) manufacturing site from Eywa Pharma Inc. for $7.7 million. Following the acquisition, Biocon invested over $30 million to modernize the facility and bring it to full operational capacity, now able to produce up to 2 billion tablets annually. The company noted that several products have already been commercialized from the site, with more in the pipeline.
Biocon described the Cranbury facility as a strategic advancement in its U.S. operations, enabling it to be closer to patients and healthcare providers, bolster supply-chain resilience, and strengthen its manufacturing footprint in a key market. The choice of New Jersey reflects the state’s long-standing position as a hub for life sciences and pharmaceutical manufacturing, offering access to skilled talent and a mature ecosystem.
“This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”
Siddharth Mittal
Chief Executive Officer and Managing Director
Siddharth Mittal
Chief Executive Officer and Managing Director